Advanced Gastric Cancer Clinical Trial
— FRUTIGAOfficial title:
A Phase III Study to Evaluate the Efficacy and Safety of Fruquintinib in Combination With Paclitaxel Versus Paclitaxel Alone in Second Line Gastric Cancer
Verified date | August 2022 |
Source | Hutchison Medipharma Limited |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Fruquintinib once daily in 4 weeks treatment cycle (three weeks on and one week off) in combination with Paclitaxel 80mg/㎡(day1, 8, 15 of 4 weeks cycle) was well tolerated and demonstrated encouraging preliminary clinical antitumor activity in patients with advanced GC in ph1b/2 study. This study is aimed to evaluate the efficacy and safety of Fruquintinib in combination with Paclitaxel in the treatment of patients with aGC who have progressed after first line standard chemotherapy.
Status | Active, not recruiting |
Enrollment | 703 |
Est. completion date | November 2022 |
Est. primary completion date | September 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Signed informed consent - Histologically or cytologically confirmed gastric or gastroesophageal junction adenocarcinoma - Metastatic disease or locally advanced, unresectable disease - Disease progression during or within 4 months after the last dose of the first-line therapy (with platinum/fluoropyrimidine ) - Adequate hepatic, renal, heart, and hematologic functions - At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan) - Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure - Good performance status Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 to 1 Exclusion Criteria: - Pregnant or lactating women - Any factors that influence the usage of oral administration - Evidence of CNS metastasis - Intercurrence with one of the following: non-controlled hypertension, coronary artery disease, arrhythmia and heart failure - Abuse of alcohol or drugs - Less than 4 weeks from the last clinical trial - Previous treatment with VEGFR inhibition - Disability of serious uncontrolled intercurrence infection - Proteinuria = 2+ (1.0g/24hr) - Have evidence or a history of bleeding tendency within two months of the enrollment randomization, regardless of seriousness - Within 12 months before the first treatment occurs artery/venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack) etc. - Within 6 months before the first treatment occurs acute myocardial infarction, acute coronary syndrome or CABG - Bone fracture or wounds that was not cured for a long time - Coagulation dysfunction, hemorrhagic tendency or receiving anticoagulant Therapy - The tumor invades a large vessel structure, such as the pulmonary artery, superior vena cava, or inferior vena cava |
Country | Name | City | State |
---|---|---|---|
China | Hutchison Medi Pharma Investigational sites | Beijing | |
China | Hutchison Medi Pharma Investigational Site | Guangzhou | Guangdong |
China | Hutchison Medi Pharma Investigational sites | Hangzhou | Zhejiang |
China | Hutchison Medi Pharma Investigational site | Harbin | Heilongjiang |
China | Hutchison Medi Pharma Invesigational sites | Hefei | Anhui |
China | Huchison Medi Pharma Investigational site | Nanjing | Jiangsu |
China | Hutchison Medi Pharma Investigational site | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Hutchison Medipharma Limited | Sun Yat-sen University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall survival (OS) | every two months follow up after EOT observation period at 30 days after the last medication | from randomization until death due to any cause, assessed up to 3 year | |
Primary | Progression free survival (PFS) | PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. | from the date of randomization to the date of the first documented progressive disease or date of death due to any cause, assessed up to 1 year] | |
Secondary | Objective response rate (ORR) | Tumor assessment will be performed using radiography method every 8 weeks until the occurrence of progressive disease (PD), using RECIST v 1.1 | from randomization up to progressive disease or EOT due to any cause, assessed up to 1 year | |
Secondary | Disease control rate (DCR) | Tumor assessment will be performed using radiography method every 8 weeks until the occurrence of progressive disease (PD), using RECIST v 1.1 | from randomization up to progressive disease or EOT due to any cause, assessed up to 1 year | |
Secondary | Safety and tolerance evaluated by incidence, severity and outcomes of AEs | Safety and tolerance will be evaluated by incidence, severity and outcomes of AEs and categorized by severity in accordance with the NCI CTC AE Version 4.03 | from first dose to 30 days post the last dose | |
Secondary | Duration of response, DOR | DOR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1. | : From the first documented PR or CR until the first documented PD or death,assessed up to 2 years | |
Secondary | The European Organization for Reasearch and Treatment of Cancer(EORTC ) Quality of Life Questionnaire-Core 30 V3.0 (QLQ-C30 v3.0) | EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures global health status. There are 30 items in total, which can be divided into 15 fields. Five functional scales: physical function, role function, cognitive function, emotional function, social function; Three symptom scales: fatigue, pain, nausea and vomiting; Six individual measures: dyspnea, insomnia, loss of appetite, constipation, diarrhea, financial difficulties, and a global quality of life scale. The five functional scales and the global quality of life scale were scored independently. After linear transformation, the scores of all items ranged from 1 to 100, and the higher score, the higher functional level. The symptom scale was also scored independently and linearly transformed into a score from 1 to 100, with higher scores indicating more serious problems or symptoms. | Evaluation before the beginning of each treatment cycle, at the end of treatment, and at the 30 days post the last dose,up to 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05028933 -
IMC001 for Clinical Research on Advanced Digestive System Malignancies
|
Phase 1 | |
Completed |
NCT00821990 -
Second-line Therapy Versus Supportive Care for Pretreated Advanced Gastric Cancer
|
Phase 3 | |
Recruiting |
NCT04385641 -
Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer
|
N/A | |
Completed |
NCT01248403 -
A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy
|
Phase 3 | |
Not yet recruiting |
NCT01206218 -
Evaluation of Customized Treatment According to BRCA1 Assessment in Patients With Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT00976768 -
Biweekly FOLFIRI in Advanced Gastric Cancer (AGC) With Failure of Prior Taxane, Fluoropyrimidine, and Cisplatin
|
Phase 2 | |
Completed |
NCT01851941 -
A Phase II Trial of Perioperative Chemotherapy With Oxaliplatin, 5-Fluorouracil, Leucovorin(MODIFIED FOLFOX6) in Patients With Locally Advanced Operable Gastric Cancer
|
Phase 2 | |
Completed |
NCT03609359 -
Lenvatinib and Pembrolizumab Simultaneous Combination Study
|
Phase 2 | |
Completed |
NCT03350477 -
Bioinformation Therapy for Gastric Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT02935634 -
A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03579784 -
Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer
|
Phase 2 | |
Completed |
NCT02952729 -
Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2
|
Phase 1 | |
Recruiting |
NCT02072317 -
Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer
|
Phase 2 | |
Terminated |
NCT01402401 -
Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
|
Phase 2 | |
Completed |
NCT01503372 -
FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer
|
Phase 2 | |
Completed |
NCT01472250 -
A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China
|
N/A | |
Recruiting |
NCT01015339 -
Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
|
Phase 3 | |
Completed |
NCT00842491 -
Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer
|
Phase 2 | |
Completed |
NCT02071043 -
Trial of Xeloda and Oxaliplatin (XELOX) as Neo-adjuvant Chemotherapy Followed by Surgery in Advanced Gastric Cancer Patients With Para-aortic Lymph Node Metastasis
|
Phase 2 | |
Completed |
NCT01441336 -
Laparoscopic Gastrectomy for Advanced Gastric Cancer
|
Phase 2 |